Nevro Corp (NYSE:NVRO)
$ 4.58 0.26 (6.02%) Market Cap: 171.62 Mil Enterprise Value: 141.17 Mil PE Ratio: 0 PB Ratio: 0.63 GF Score: 43/100

Nevro Corp at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 05:00PM GMT
Release Date Price: $118.27 (+3.46%)
Robert Justin Marcus
JP Morgan Chase & Co, Research Division - Analyst

Good morning, everyone. I'm Robbie Marcus, a Medical Device Analyst at JPMorgan, and I'm very happy to introduce our next speaker, Keith Grossman, Chairman, CEO and President of Nevro. Keith?

D. Keith Grossman
Nevro Corp. - Chairman of the Board, CEO & President

Thank you, Robbie. Good morning, everyone. Welcome to those of you here in the room and those of you joining on the web. My name is Keith Grossman. I will certainly make some forward-looking statements, so I'd refer you to the safe harbor language in our SEC filings.

So Nevro is a leading participant in the spinal cord stimulation for chronic pain market. What does that mean? What we're doing here is we're using predominantly 1 of 2 mechanisms of action to either mask or interrupt the pain signal traveling from the pain site to the brain. This has become a sizable market of about 100,000 patients treated annually. About 80% of that market, by the way, is here in the U.S.

The worldwide market for these

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot